Importance/Objective: Adverse Drug Reactions (ADRs) are unavoidable, but recognizing and addressing ADRs early can improve wellness and prevent permanent injury. We suggest that available medical information and digital/electronic methods could be used to manage this major healthcare problem for individual patients in real time. Methods: We searched the available digital applications and three literature databases using the medical subject heading terms, adverse drug reaction reporting systems or management, filtered by clinical trial or systemic reviews, to detect publications with data about ADR identification and management approaches. We reviewed the reports that had abstract or summary data or proposed or implemented methods or systems with potential to identify or manage ADRs in clinical settings. Results: The vast majority of the 481 reports used retrospectively collected data for groups of patients or were limited to surveying one population group or class of medication. The reports showed potential and definite associations of ADRs for specific drugs and problems, mostly, but not exclusively, for patients in hospitals and nursing homes. No reports described complete methods to collect comprehensive data on ADRs for individual patients in a healthcare system. The digital applications have ADR information, but all are too cumbersome or incomplete for use in active clinical settings. Several studies suggested that providing information about potential ADRs to clinicians can reduce these problems. Conclusion and Relevance: Although investigators and government agencies agree with the need, there is no comprehensive ADR management program in current use. Informing the patient’s healthcare practitioners of potential ADRs at the point of service has the potential for reduction of these complications, which should improve healthcare and reduce unneeded costs.
References
[1]
World Health Organization (1984) Collaborating Centers for International Drug Monitoring. World Health Organization, Geneva.
[2]
Sultana, J., Jerking, P. and Trifirò, G. (2013) Clinical and Economic Burden of Adverse Drug Reactions. Journal of Pharmacology and Pharmacotherapeutics, 4, S73-S77.
https://doi.org/10.4103/0976-500X.120957
[3]
Shehab, N., Lovegrove, M.C., Geller, A.I., Rose, K.O., Weidle, N.J. and Budnitz, D.S. (2016) US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA, 316, 2115-2125. https://doi.org/10.1001/jama.2016.16201
[4]
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse Drug Reactions as Cause of Admission to Hospital: Prospective Analysis of 18820 Patients. BMJ, 329, 15-19.
https://doi.org/10.1136/bmj.329.7456.15
[5]
Wolfe, D., Yazdi, F., Kanji, S., Burry, L., Beck, A., Butler, C., Esmaeilisaraji, L., Hamel, C., Hersi, M., Skidmore, B., Moher, D. and Hutton, B. (2018) Incidence, Causes, and Consequences of Preventable Adverse Drug Reactions Occurring in Inpatients: A Systematic Review of Systematic Reviews. PLOS ONE, 13, e0205426.
https://doi.org/10.1371/journal.pone.0205426
[6]
Brennan, T.A., Leape, L.L., Laird, N.M., Hebert, L., Localio, A.R., Lawthers, A.G., et al. (1991) Incidence of Adverse Events and Negligence in Hospitalized Patients: Results of the Harvard Medical Practice Study I. The New England Journal of Medicine, 324, 370-376. https://doi.org/10.1056/NEJM199102073240604
[7]
Bates, D.W., Cullen, D., Laird, N., Petersen, L., Small, S., Servi, D., et al. (1995) Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. JAMA, 274, 29-34. https://doi.org/10.1001/jama.1995.03530010043033
[8]
Lazarou, J., Pomeranz, B. and Corey, B. (1998) Incidence of Drug Adverse Reactions in Hospitalized Patients. A Meta-Analysis. JAMA, 279, 1200-1205.
https://doi.org/10.1001/jama.279.15.1200
[9]
Nolan, L. and O’Malley, K. (1988) Prescribing for the Elderly Part I: Sensitivity of the Elderly to Adverse Drug Reactions. Journal of the American Geriatrics Society, 36, 142-149. https://doi.org/10.1111/j.1532-5415.1988.tb01785.x
[10]
Gurwitz, J.H., Field, T.S., Harrold, L.R., Rothschild, J., Debellis, K., Seger, A.C., Cadoret, C., Fish, L.S., Garber, L., Kelleher, M. and Bates, D.W. (2003) Incidence and Preventability Adverse Drug Events among Older Patients in the Ambulatory Setting. JAMA, 289, 107-116. https://doi.org/10.1001/jama.289.9.1107
[11]
Otero, M.J., Toscano, G., Galván-Banqueri, M., Martinez-Sotelo, J. and Santos-Rubio, M.D. (2021) Utility of a Trigger Tool (TRIGGER-CHRON) to Detect Adverse Events Associated with High-Alert Medications in Patients with Multimorbidity. European Journal of Hospital Pharmacy, 28, E41-E46.
https://doi.org/10.1136/ejhpharm-2019-002126
[12]
Jick, H. (1984) Adverse Drug Reactions: The Magnitude of the Problem. Journal of Allergy and Clinical Immunology, 74, 555-557.
https://doi.org/10.1016/0091-6749(84)90106-4
[13]
Classen, D.C., Pestotnik, S.L., Evans, R.S., et al. (1997) Adverse Drug Events in Hospitalized Patients. Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA, 277, 301-306. https://doi.org/10.1001/jama.1997.03540280039031
[14]
Schatz, S.N. and Weber, R.J. (2015) Adverse Drug Reactions. In: Lee, M.W. and Murphy, J.E., Eds., PSAP 2015 Book 2 CNS/Pharmacy Practice, American College of Clinical Pharmacy, Lenexa, 5-26.
[15]
Panagioti, M., Khan, K., Keers, R.N., Abuzour, A., Phipps, D., Kontopantelis, E., et al. (2019) Prevalence, Severity, and Nature of Preventable Patient Harm across Medical Care Settings: Systematic Review and Meta-Analysis. BMJ, 366, L4185.
https://doi.org/10.1136/bmj.l4185
[16]
National Patient Safety Foundation (2015) Free from Harm: Accelerating Patient Safety Improvement Fifteen Years after to Err Is Human. National Patient Safety Foundation, Boston.
https://www.aorn.org/docs/default-source/guidelines-resources/position-statements/endorsed-documents/freefromharm_execsummary.pdf?sfvrsn=a09a1e82_1
[17]
Khalil, H., Shahid, M. and Roughead, L. (2017) Medication Safety Programs in Primary Care: A Scoping Review. JBI Database of Systematic Reviews and Implementation Reports, 15, 2512-2526. https://doi.org/10.11124/JBISRIR-2017-003436
[18]
Smith, J.C., Chen, Q., Denny, J.C., Roden, D.M., Johnson, K.B. and Miller, R.A. (2018) Evaluation of a Novel System to Enhance Clinicians’ Recognition of Preadmission Adverse Drug Reactions. Applied Clinical Informatics, 9, 313-325.
https://doi.org/10.1055/s-0038-1646963
[19]
Smith, J.C., Denny, J.C., Chen, Q., Nian, H., Spickard, A., Rosenbloom, S.T. and Miller, R.A. (2013) Lessons Learned from Developing a Drug Evidence Base to Support Pharmacovigilance. Applied Clinical Informatics, 4, 596-617.
https://doi.org/10.4338/ACI-2013-08-RA-0062
[20]
Wu, L., Ingle, T., Liu, Z., et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
[21]
Demner-Fushman, D., et al. (2018) A Dataset of 200 Structured Product Labels Annotated for Adverse Drug Reactions. Scientific Data, 5, Article ID: 180001.
https://doi.org/10.1038/sdata.2018.1
[22]
Wu, L.H., Ingle, T., Liu, Z.C., et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
[23]
Bates, D.W. (2000) Using Information Technology to Reduce Rates of Medication Errors in Hospitals. BMJ, 320, 788-791. https://doi.org/10.1136/bmj.320.7237.788
[24]
Harris, Y., Hu, D.J., Lee, C., Mistry, M., York, A. and Johnson, T.K. (2015) Advancing Medication Safety: Establishing a National Action Plan for Adverse Drug Event Prevention. The Joint Commission Journal on Quality and Patient Safety, 41, 351-360. https://doi.org/10.1016/S1553-7250(15)41046-3
Marcum, Z.A., Arbogast, K.L., Behrens, M.C., Logsdon, M.W., Francis, S.D., Jeffery, S.M., Aspinall, S.L., Hanlon, J.T. and Handler, S.M. (2013) Utility of an Adverse Drug Event Trigger Tool in Veterans Affairs Nursing Facilities. The Consultant Pharmacist, 28, 99-109. https://doi.org/10.4140/TCP.n.2013.99
[27]
Classen, D.C., Pestotnik, S.L., Evans, R.S. and Burke, J.P. (2005) Computerized Surveillance of Adverse Drug Events in Hospital Patients. Quality & Safety in Health Care, 14, 221-225.
[28]
Habib, B., Tamblyn, R., Girard, N., Eguale, T. and Huang, A. (2021) Detection of Adverse Drug Events in E-Prescribing and Administrative Health Data: A Validation Study. BMC Health Services Research, 21, 376-403.
https://doi.org/10.1186/s12913-021-06346-y
[29]
O’Connor, M.N., O’Sullivan, D., Gallagher, P.F., Eustace, J., Byrne, S. and O’Mahony, D. (2016) Prevention of Hospital-Acquired Adverse Drug Reactions in Older People Using Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right Treatment Criteria: A Cluster Randomized Controlled Trial. Journal of the American Geriatrics Society, 64, 1558-1566. https://doi.org/10.1111/jgs.14312
[30]
PDR Drug Information Fully Searchable Fully Digital. http://www.pdr.net
Questions and Answers on FDA’s Adverse Event Reporting System (FAERS).
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/
[39]
DeRhodes, K.H. (2019) the Dangers of Ignoring the Beers Criteria—The Prescribing Cascade. JAMA Internal Medicine, 179, 863-864.
https://doi.org/10.1001/jamainternmed.2019.1288
[40]
Nguyen, P.V. and Spinelli, C. (2016) Prescribing Cascade in an Elderly Woman. Canadian Pharmacists Journal, 149, 122-124.
https://doi.org/10.1177/1715163516640811
[41]
The Prescribing Cascade.
https://www.nps.org.au/assets/bfed344b681dd636-b041584d99e7-ca3f75bcf6b64e70d9dde28acdc1db3afe4ec255b4828f2084ec8c611b0c.pdf
[42]
Sternberg, S.A., Guy-Alfandary, S. and Rochon, P.A. (2021) Prescribing Cascades in Older Adults. Canadian Medical Association Journal, 193, E215.
https://doi.org/10.1503/cmaj.201564
[43]
Brody, J. (2020) The Risks of the Prescribing Cascade. The New York Times.
[44]
Wang, J., Shen, J.Y., Conwell, Y., Podiatry, E.J., Caprio, T.V., Nathan, K., Yu, F., Rams, D.E.E., Fick, D.M., Mixon, A.S. and Simmons, S.F. (2022) Implementation Considerations of Deprescribing Interventions: A Scoping Review. Journal of Internal Medicine. https://doi.org/10.1111/joim.13599
[45]
National Action Plan for Adverse Drug Event Prevention.
https://health.gov/sites/default/files/2019-09/ADE-Action-Plan-Introduction.pdf
[46]
Department of Health and Human Services Part 1. Overview Information.
https://grants.nih.gov/grants/guide/pa-files/pa-20-028.html
[47]
AHRQ Grants by State.
https://www.ahrq.gov/funding/grant-mgmt/grants-by-state.html
[48]
Gandhi, T.K., Weingart, S.N., Borus, J., Seger, A.C., Peterson, J., Burdick, E., Seger, D.L., Shu, K., Federico, F., Leape, L.L. and Bates, D.W. (2003) Adverse Drug Events in Ambulatory Care. The New England Journal of Medicine, 348, 1556-1564.
https://doi.org/10.1056/NEJMsa020703
[49]
Gandhi, T.K., Burstin, H.R., Cook, E.F., Puopolo, A.L., Haas, J.S., Brennan, T.A. and Bates, D.W. (2000) Drug Complications in Outpatients. Journal of General Internal Medicine, 15, 149-154. https://doi.org/10.1046/j.1525-1497.2000.04199.x
[50]
Pitrou, I., Boutron, I., Ahmad, N. and Ravaud, P. (2009) Reporting of Safety Results in Published Reports of Randomized Controlled Trials. Archives of Internal Medicine, 169, 1756-1761. https://doi.org/10.1001/archinternmed.2009.306
[51]
Cross, C. (2013) Drug Reporting May Be Mandatory for Doctors. Canadian Medical Association Journal, 185, 866. https://doi.org/10.1503/cmaj.109-4487
[52]
Step 5: FDA Post-Market Drug Safety Monitoring.
https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring
[53]
MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
[54]
Alomar, M., Tawfiq, A.M., Hassan, N. and Palaian, S. (2020) Post Marketing Surveillance of Suspected Adverse Drug Reactions through Spontaneous Reporting: Current Status, Challenges and the Future. Therapeutic Advances in Drug Safety, 11, 1-11. https://doi.org/10.1177/2042098620938595
Moore, V.R., Glassman, P.A., Au, A., Good, C.B., Leadholm, T.C. and Cunningham, F.E. (2019) Adverse Drug Reactions in the Veterans Affairs Healthcare System: Frequency, Severity, and Causative Medications Analyzed By Patient Age. American Journal of Health-System Pharmacy, 76, 312-319.
https://doi.org/10.1093/ajhp/zxy059
[57]
Adverse Drug Event Reporting and Monitoring.
https://www.va.gov/vhapublications/viewpublication.asp?pub_id=8831
[58]
Bruno, H., Stricker, C. and Psaty, B. (2004) Detection, Verification, and Quantification of Adverse Drug Reactions. British Medical Journal, 329, 44-47.
https://doi.org/10.1136/bmj.329.7456.44
[59]
Agbabiaka, T.B., Savovic, J. and Ernst, E. (2008) Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review. Drug Safety, 31, 21-37.
https://doi.org/10.2165/00002018-200831010-00003
[60]
Wu, L., Ingle, T., Liu, Z. et al. (2019) Study of Serious Adverse Drug Reactions Using FDA-Approved Drug Labeling and MedDRA. BMC Bioinformatics, 20, Article No. 97. https://doi.org/10.1186/s12859-019-2628-5
[61]
Lee, C.Y. and Chen, Y.P. (2021) Prediction of Drug Adverse Events Using Deep Learning in Pharmaceutical Discovery. Briefings in Bioinformatics, 22, 1884-1901.
https://doi.org/10.1093/bib/bbaa040
[62]
Yu, Z., Wu, Z., Li, W., Liu, G. and Tang, Y. (2022) ADENet: A Novel Network-Based Inference Method for Prediction of Drug Adverse Events. Briefings in Bioinformatics, 23, bbab580. https://doi.org/10.1093/bib/bbab580
